

PEOPLE

Genome Pharmaceuticals (Munich, Germany) has announced the appointment of **Metin Colpan** to its supervisory board. Dr. Colpan is cofounder, CEO, and president of Qiagen NV. He will take the board seat vacated by Hans Lehrach, one of Genome Pharmaceuticals' scientific founders.

Leonard R. Borrmann has been named CEO of Acadia Pharmaceuticals (San Diego, CA). Dr. Borrmann was most recently vice president of business development for Allergan.

DynaGen (Cambridge, MA) has announced that its board of directors has approved the appointment of **C. Robert Cusick** to the position of chairman and director. Mr. Cusick was formerly the CEO of International Murex Technology.

George A. deVeber and **Jan Oudenes** have been named to the board of directors of Hyal Pharmaceutical (Mississauga, Ontario, Canada). Dr. deVeber is a former vice president, medical affairs at Baxter, and is currently the medical director of Vasogen. Dr. Oudenes is president of Torcan Chemical Ltd.

James M. Frates has been appointed vice president and chief financial officer at Alkermes (Cambridge, MA). Mr. Frates was previously a vice president of BancAmerica Robertson Stephens.

Genentech (South San Francisco, CA) has announced the promotions of **Dennis J. Henner** to senior vice president of research and **Stephen Juelsgaard** to senior vice president, general counsel and secretary. Dr. Henner previously served as vice president of research and has headed Genentech's research effort since 1996. Dr. Juelsgaard was most recently vice president, general counsel and secretary.

Guilford Pharmaceuticals (Baltimore, MD) has announced the addition of **Gregory M. Hockel** (right) as vice president, regulatory affairs and **Dana C. Hilt** as vice president, clinical research. Dr. Hockel joins Guilford from British Biotech, where he has worked since 1994 as vice president of regulatory affairs. Dr. Hilt was most recently director of neuroscience at Amgen.



Michael E. Hogan, a professor at Baylor College of Medicine's department of molec-

ular physiology and biophysics, has been named chief scientific officer at Genometrix (The Woodlands, TX). Dr. Hogan has served as the company's scientific advisor since its founding in 1993.

Louis P. Lacasse has been elected to the board of directors of Targeted Genetics (Seattle, WA). Mr. Lacasse is president of GeneChem Management, manager of GeneChem Technologies Venture Fund LP, which recently led a \$13 million private placement of Targeted Genetics' common stock. The board simultaneously accepted the resignation of **Stephen A. Duzan**, who will pursue other interests. Mr. Duzan served as a director of Targeted Genetics since 1989.

Brigid A. Makes has been appointed chief financial officer of OraVax (Cambridge, MA). Ms. Makes joins OraVax from Haemonetics Corp., where she most recently held the position of vice president, finance and CFO.

PowderJect Pharmaceuticals (Fremont, CA) has announced that **Steven J. Prestrelski** has joined the company in the newly created position of vice president, biopharmaceuticals. Dr. Prestrelski joins PowderJect from Alza, where he was director, biopharmaceutical R&D.



Eurona Medical (Uppsala, Sweden) has named **Thomas Pollare** to the position of vice president, business development. He joins Eurona from Pharmacia & Upjohn, where he was most recently vice president, development.

IDEC Pharmaceuticals (San Diego, CA) has announced the appointment of **William R. Rohn** as chief operating officer. Mr. Rohn has served as senior vice president, commercial operations since 1994. IDEC has also named **Mark C. Wiggins** vice president, business development. Mr. Wiggins was previously vice president, business development and marketing at Hybridon.

Paul M. Simon has been appointed vice president, research of VIMRX Pharmaceuticals (Wilmington, DE). Dr. Simon previously served as director of drug development at Neose Technologies.

Biovector Therapeutics (Toulouse, France) has appointed **Alain Thierry** director of gene

therapy and delivery. Dr. Thierry, previously with the US National Institutes of Health, is the inventor of a DNA delivery technology Biovector has licensed from the NIH.

John F. Warner has been appointed vice president of research at Megabios (Burlingame, CA). Dr. Warner was previously vice president, gene therapy and immunology at Inex Pharmaceuticals.

Cambridge NeuroScience (Cambridge, MA) has named **Harry W. Wilcox** president and CEO. Mr. Wilcox, who was previously CFO and senior vice president of business development, also joins the board. **Elkan Gamzu**, former president and CEO, will continue to serve as a consultant to the company.

Viragen (Plantation, FL) has announced the appointment of **Patrick Yeramian** as vice president and chief medical officer. For the past 5 years, Dr. Yeramian has served as director of clinical research for G.D. Searle, managing worldwide clinical development of therapies for immunodeficiencies secondary to HIV and cancer.

**TIME IS MONEY
SAVE BOTH**

DNA SEQUENCING
\$1.25 per base pair

PRIMERS
\$1.00 per base

We Also Offer:

ssDNA Sequencing..... \$50 / Run
Peptide Synthesis..... \$15.50/ A.A.
Amino Acid Analysis..... \$84 / Sample
Protein Sequencing..... \$ 30 / A.A.*
* plus setup charge

For More Information Call Us Today

800-343-8998

<http://www.ssr4dna.com>

Southwest Scientific Resources Inc.

DEPENDABLE * ACCURATE
AFFORDABLE